
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Efficacy in Preclinical Studies
Tonix Pharmaceuticals presented groundbreaking preclinical data for TNX-801, a single-dose mpox vaccine candidate that demonstrates robust protection across diverse animal subjects, including those with compromised immune systems, with durable immunity lasting six months.
Read full story






















